Looking At The Narrative For Hikma Pharmaceuticals LSE HIK After Analyst Split On Fair Value [Yahoo! Finance]
HIKMA PHARMS PLC S/ADR (HKMPY)
NASDAQ:AMEX Investor Relations:
hikma.com/en/investors.html
Company Research
Source: Yahoo! Finance
The latest research includes optimistic calls in the £23.00 to £25.10 range and a more cautious £16.00 target, so the new fair value sits closer to the middle of that spread. Stay with this article to see how you can track these shifting targets and keep on top of the story as it evolves. Stay updated as the Fair Value for Hikma Pharmaceuticals shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Hikma Pharmaceuticals. ?? Bullish Takeaways Berenberg has taken a constructive stance on Hikma, with analyst Beatrice Fairbairn adjusting the firm's price target first to 2,510 GBp and later to 2,300 GBp while keeping a Buy rating. This signals continued confidence in the company's ability to execute despite fine tuning expectations. JPMorgan analyst Zain Ebrahim also remains supportive, keeping an Overweight rating with a 2,400 GBp price target. This places Hikma at the higher end of the current analyst target range
Show less
Read more
Impact Snapshot
Event Time:
HKMPY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HKMPY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HKMPY alerts
High impacting HIKMA PHARMS PLC S/ADR news events
Weekly update
A roundup of the hottest topics
HKMPY
News
- Hikma Pharmaceuticals (LON:HIK) shareholders have endured a 29% loss from investing in the stock five years ago [Yahoo! Finance]Yahoo! Finance
- Hikma launches TYZAVAN™ (vancomycin injection, USP) in the USPR Newswire
- How Recent Developments Are Shaping the Hikma Pharmaceuticals Story and Its Valuation [Yahoo! Finance]Yahoo! Finance
- Hikma Pharmaceuticals PLC (HKMPY) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
- Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution [Yahoo! Finance]Yahoo! Finance